I

    Intuitive Surgical Inc (ISRG)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $376.86
    +4.26 (+1.14%)

    Market Cap: $135.02B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    90%(36/40)
    Avg Surprise
    +14.45%
    Streak
    14 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$2.64
    Range$2.53 - $2.76
    23 analysts
    EPS Revisions
    2
    0
    7d
    21
    2
    30d
    EPS Estimate Drift
    90d ago$2.58-2.2%
    60d ago$2.59-2.0%
    30d ago$2.63-0.3%
    7d ago$2.64-0.1%
    Current$2.64
    Revenue Consensus
    $2.9B
    Range$2.8B - $3.0B
    24 analysts
    Period ending Dec 31, 2026
    EPS Consensus$3.54
    Range$3.41 - $3.83
    26 analysts
    Revenue Consensus
    $3.4B
    Range$3.2B - $4.0B
    32 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$3.54---
    Sep 26EST
    		-$2.64---
    Jun 26
    Reported Jul 16
    		$2.80$2.02+38.61%Beat+27.9%
    Mar 26
    Reported Apr 21
    		$2.50$2.11+18.48%Beat+38.1%
    Dec 25
    Reported Jan 22
    		$2.53$2.27+11.45%Beat+14.5%
    Sep 25
    Reported Oct 21
    		$2.40$1.99+20.60%Beat+30.4%
    Jun 25
    Reported Jul 22
    		$2.19$1.92+14.06%Beat+23.0%
    Mar 25
    Reported Apr 22
    		$1.81$1.73+4.62%Beat+20.7%
    Dec 24
    Reported Jan 23
    		$2.21$1.79+23.46%Beat+38.1%
    Sep 24
    Reported Oct 17
    		$1.84$1.64+12.20%Beat+26.0%
    Jun 24
    Reported Jul 18
    		$1.78$1.54+15.58%Beat+25.4%
    Mar 24
    Reported Apr 18
    		$1.50$1.42+5.63%Beat+22.0%
    Dec 23
    Reported Jan 23
    		$1.60$1.49+7.38%Beat+30.1%
    Sep 23
    Reported Oct 19
    		$1.46$1.42+2.82%Beat+22.7%
    Jun 23
    Reported Jul 20
    		$1.42$1.33+6.77%Beat+24.6%
    Mar 23
    Reported Apr 18
    		$1.23$1.20+2.50%Beat+8.8%
    Dec 22
    Reported Jan 24
    		$1.23$1.25-1.60%Miss-5.4%
    Sep 22
    Reported Oct 18
    		$1.19$1.12+6.25%Beat+0.0%
    Jun 22
    Reported Jul 21
    		$1.14$1.20-5.00%Miss-13.0%
    Mar 22
    Reported Apr 21
    		$1.13$1.08+4.63%Beat-3.4%
    Dec 21
    Reported Jan 20
    		$1.30$1.28+1.56%Beat+9.2%
    Sep 21
    Reported Oct 19
    		$1.19$1.16+2.59%Beat+29.3%
    Jun 21
    Reported Jul 20
    		$1.31$1.02+28.43%Beat+254.1%
    Mar 21
    Reported Apr 20
    		$1.17$0.88+32.95%Beat+30.0%
    Dec 20
    Reported Jan 21
    		$1.19$1.04+14.42%Beat+2.6%
    Sep 20
    Reported Oct 15
    		$0.92$0.68+35.29%Beat-19.3%
    Jun 20
    Reported Jul 21
    		$0.37$0.16+131.25%Beat-65.7%
    Mar 20
    Reported Apr 16
    		$0.90$0.85+5.88%Beat+3.4%
    Dec 19
    Reported Jan 23
    		$1.16$1.13+2.65%Beat+17.2%
    Sep 19
    Reported Oct 17
    		$1.14$1.00+14.00%Beat+21.3%
    Jun 19
    Reported Jul 18
    		$1.08$0.96+12.50%Beat+17.4%
    Mar 19
    Reported Apr 18
    		$0.87$0.90-3.33%Miss+7.4%
    Dec 18
    Reported Jan 24
    		$0.99$1.02-2.94%Miss+16.5%
    Sep 18
    Reported Oct 18
    		$0.94$0.89+5.62%Beat+2.2%
    Jun 18
    Reported Jul 19
    		$0.92$0.83+10.84%Beat+39.4%
    Mar 18
    Reported Apr 17
    		$0.81$0.69+17.39%Beat+42.1%
    Dec 17
    Reported Jan 25
    		$0.85$0.76+11.84%Beat+25.0%
    Sep 17
    Reported Oct 19
    		$0.92$0.66+39.39%Beat+33.3%
    Jun 17
    Reported Jul 20
    		$0.66$0.64+3.13%Beat-
    Mar 17
    Reported Apr 18
    		$0.57$0.55+3.64%Beat-
    Dec 16
    Reported Jan 24
    		$0.68$0.67+1.49%Beat-
    Sep 16
    Reported Oct 18
    		$0.69$0.57+21.05%Beat-

    Key Metrics

    Valuation
    P/E Ratio36.84EV/EBITDA29.32x
    Price/FCF41.41xFCF Yield2.41%
    Profitability
    Profit Margin28.40%Operating Margin33.60%
    ROE17.40%ROIC16.78%
    Financial Health
    Debt/Equity0.04xInterest CoverageN/A
    Current Ratio4.96xQuick Ratio3.91x
    Trading Statistics
    Beta1.46Avg Volume2.56M
    52-Week High$603.8852-Week Low$328.57

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$377.45
    SMA 20$382.63
    SMA 50$383.61
    SMA 200$467.59
    EMA 10$376.43
    EMA 20$378.34
    EMA 50$387.48
    EMA 200$442.51

    MACD

    Line: -2.34Signal: -1.17Hist: -1.17

    ADX

    ADX: 14.4+DI: 22.3-DI: 25.3

    Aroon & PSAR

    Aroon Up68.0
    Aroon DownN/A
    PSAR$392.38

    Bollinger Bands

    Upper Band$406.98
    Lower Band$358.27
    %B Position1273%(Upper)
    Band Width0.38

    RSI (14-Day)

    Neutral
    48.3

    Momentum Oscillators

    Stoch %K15.0
    Stoch %D10.4
    Williams %R-71.2
    ROC (10d)-3.5%
    Momentum-13.47
    CCI (20d)-59.2
    MFI (14d)50.4

    Volatility Measures

    ATR (14d)$11.46(3.0%)
    StdDev (20d)12.18
    Hist Vol31.9%(Moderate)

    Volume Flow

    VWAP$373.18
    OBV3.8M
    AD Line-35.4M
    CMF (20d)-0.014

    Volume Metrics

    Avg Vol (20d)2.5M
    Vol Ratio0.7x
    VWMA (20d)$383.49

    Pivot Points

    R3$381.75
    R2$377.57
    R1$375.08
    Pivot Point$370.91
    S1$368.43
    S2$364.25
    S3$361.76

    Advanced Oscillators

    TSI-4.40
    Ultimate Osc50.8
    KST10.53

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$2.89B$2.77B$2.87B$2.51B$2.44B$2.25B$2.41B$2.04B$2.01B$1.89B$1.93B$1.74B
    Cost of Revenue$931.90M$940.30M$961.90M$842.70M$822.10M$795.70M$771.30M$664.20M$637.20M$645.20M$650.90M$576.50M
    Gross Profit$1.96B$1.83B$1.90B$1.66B$1.62B$1.46B$1.64B$1.37B$1.37B$1.25B$1.28B$1.17B
    Operating Expenses$988.50M$975.20M$1.04B$902.70M$874.50M$879.60M$907.30M$796.60M$805.40M$776.00M$827.20M$701.40M
    R&D$370.60M$361.90M$352.90M$329.40M$313.30M$316.20M$294.70M$286.00M$280.10M$284.50M$260.10M$249.40M
    SG&A$617.90M$613.30M$687.10M$573.30M$561.20M$563.40M$612.60M$510.60M$525.30M$491.50M$567.10M$452.00M
    Operating Income$971.90M$855.30M$864.30M$759.70M$743.40M$578.10M$734.90M$577.30M$567.30M$469.40M$450.20M$465.80M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$1.05B$940.40M$955.60M$855.20M$832.10M$668.50M$809.80M$671.00M$654.50M$538.50M$515.90M$522.00M
    Income Tax Expense$231.40M$114.40M$156.10M$146.00M$167.90M$-35,200,000$121.80M$100.40M$123.00M$-8,900,000$-94,800,000$102.20M
    Net Income$823.20M$826.00M$799.50M$709.20M$664.20M$703.70M$688.00M$570.60M$531.50M$547.40M$610.70M$419.80M
    EBITDA$1.28B$1.13B$1.13B$1.01B$986.80M$800.40M$940.10M$784.30M$755.40M$650.40M$642.10M$638.60M
    EBIT$1.05B$940.40M$955.60M$855.20M$832.10M$668.50M$809.80M$671.00M$654.50M$538.50M$515.90M$522.00M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    Globus Medical Grew Earnings 56% On 6% Revenue. The Robotics Line Went Backwards.

    Q2 non-GAAP EPS $1.34, up 55.8% y/y; revenue $789.6M, +5.9%; company kept revenue guide $3.18-3.22B and raised adjusted EPS to $4.95-5.05 from $4.70-4.80 Enabling Technologies revenue fell 25.8% to $26.1M, now 3.3% of sales - robotics is a marginal, shrinking contributor, so treat any robotics pull-through thesis as unproven Adjusted gross margin expanded 200bps to 69.4%; SG&A down $16.8M to $286.8M, SG&A margin improved 440bps to 36.3%; R&D fell to 4.6% of sales - 40-140bps of margin tailwind likely temporary 1H operating cash flow $412.1M vs $255.2M y/y; 1H free cash flow $339.3M vs $172.5M; cash and marketable securities $840.5M, net cash ~$6.26/sh, trading near 15x 2024E EPS or 13.3x trailing FCF Neuromodulation down 14.3% and not expected to recover until late Q4; U.S. sales +3% with spine +7% while international +18% - prefer mid-$70s entry given cost-driven EPS gains and revenue risks

    Unknown Author
    •
    8/11/26
    •
    179
    Medical Devices
    value investing
    Also mentions:
    MDT
    ISRG

    The Biggest Healthcare Disconnect In Decades - And The Stocks I’m Watching

    Healthcare has hit a 26-year relative low, but weakness alone does not make the sector a buy. AI-led capital flows, patent cliffs, IRA pricing pressure, and GLP-1 disruption explain much of the selloff. I prefer selective exposure: picks-and-shovels, AI-driven platforms, and discounted turnarounds over broad healthcare ETFs. TMO, WST, LLY, ISRG, and PFE stand out as stocks to watch, each with different risk/reward profiles.

    Unknown Author
    •
    5/25/26
    •
    435
    Healthcare Stocks
    Dividend Investing
    value investing
    Also mentions:
    TMO
    WST
    LLY
    ISRG
    PFE

    The Aristocrat Nobody Wanted: Why (MDT) Is Worth a Second Look Right Now

    (MDT) has raised its dividend for 48 consecutive years, yet trades at just 14x forward earnings. On a trailing basis it is 24x vs. (ISRG) at 57x and (SYK) at 40x. The 5-year dividend CAGR is 4.4%, slowing to 2.0% over three years. This is a yield anchor at 3.3%, not a fast compounder. Payout ratio of 50.2% keeps the streak sustainable. FCF yield sits near 4.87% with $5.41B in trailing free cash flow. Ten straight years of positive FCF. The income is backed by real cash generation. Revenue grew 8.7% in the most recent quarter, the company's strongest enterprise growth in 10 quarters. Full-year guidance raised then reiterated. Two consecutive beats matter. Blended fair value from multiple sources lands near $107-$108 vs. current price near $86, implying roughly 24-25% upside before the 3.3% yield. GNG Research internal FV is $94.01. EPS beat rate over the last 8 quarters: 100%. The market is pricing this like a business that disappoints. The data from the GNG Research terminal shows otherwise.

    Unknown Author
    •
    4/8/26
    •
    138
    dividend aristocrats
    value investing
    Medical Devices
    Also mentions:
    ISRG
    ABT
    SYK

    Why TransMedics Stock is a Buy for Long-Term Investors

    TransMedics is replacing a 60-year-old organ-transport method with its FDA-approved OCS platform, which keeps hearts, lungs, and livers alive and functioning during transit — a massive step-change in reliability and outc Business model now prints cash: $250K consoles + $80–100K per-procedure recurring revenue + the scaling National OCS Program (NOP) aircraft fleet. Margins expanding, FCF inflection is real. Financials are inflecting sharply: EPS beat (+83%), strong operating leverage, rising gross margins, and guidance moving higher even with temporary revenue noise. Short-term volatility ≠ broken thesis: Stock recently sold off on a slight revenue miss and high short interest, but fundamental adoption trends remain strong across transplant centers. Long-term runway is substantial: Multi-organ expansion, NOP scaling, higher utilization rates, and future indications (including kidney) create years of growth. GNG Research Rating — BUY on weakness: Best accumulation zone is sub-$110, with long-term fair value well above current levels based on sustained growth, rising margins, and expanding TAM.

    Unknown Author
    •
    11/14/25
    •
    266
    medical-technology
    healthcare-innovation
    organ-transplant
    growth-stocks
    Also mentions:
    ISRG
    SYK
    MDT
    ABT
    EW

    Government Contracts

    Gov Obligations (TTM)
    -$191854
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    -100.5%
    Active Awards
    17
    New Awards (TTM)
    1
    Avg Remaining Term
    4.0 mo

    Top agency: Department of Defense at 78.9% of trailing twelve month obligations across 2 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    75N98026P00872Department of Health and Human ServicesNational Institutes of Health$100040Jun 26, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?

    Intuitive Surgical (ISRG) is prioritizing aggressive investment in research and development (R&D) to ensure long-term growth, despite current macroeconomic challenges and competitive pressures. This strategy focuses on innovation, including AI/ML and robotics, to expand into new disease areas like GI, cardiac, and lung interventions, rather than short-term cost-cutting. The company believes this will broaden its addressable market and strengthen its competitive moat, similar to peers like Edwards Lifesciences and Glaukos who also maintain substantial R&D spending.

    TradingView•9/1/26•
    Bullish

    Intuitive Surgical Inc. stock outperforms competitors on strong trading day

    Intuitive Surgical Inc. (ISRG) shares rose 1.14% to $376.86, outperforming the broader market which saw the S&P 500 and Dow Jones Industrial Average decline. This marks the second consecutive day of gains for the stock. The trading session was otherwise grim for the stock market.

    MarketWatch•8/31/26•
    Bullish

    Thornburg Investment Management Inc. Has $196.49 Million Stock Position in Medtronic PLC $MDT

    Thornburg Investment Management Inc. significantly increased its stake in Medtronic PLC, purchasing an additional 494,653 shares, bringing its total holding to 2.51 million shares valued at $196.49 million. Institutional investors collectively own 82.06% of Medtronic, which currently holds a "Moderate Buy" consensus rating from analysts. The company recently reported strong quarterly earnings with revenue of $9.81 billion and EPS of $1.55, both exceeding estimates, and declared a $0.72 quarterly dividend.

    MarketBeat•8/30/26•
    Neutral

    Nichols & Pratt Advisers LLP MA Sells 15,285 Shares of Medtronic PLC $MDT

    Nichols & Pratt Advisers LLP MA has reduced its stake in Medtronic PLC (NYSE:MDT) by 9.8%, selling 15,285 shares and retaining holdings valued at $11.04 million. Despite this sale, institutional investors own a significant 82.06% of the company. Medtronic recently exceeded quarterly expectations with $1.55 EPS and $9.81 billion in revenue, also announcing a quarterly dividend of $0.72.

    MarketBeat•8/30/26•
    Somewhat-Bullish

    Intuitive Surgical stock holds above $372 as investors weigh recent valuation resets

    Intuitive Surgical stock is trading around $372, significantly below its 52-week high, with some valuation models indicating a downside risk of up to 42%. Despite strong fundamentals, including a robust balance sheet and recurring revenue from its da Vinci robotic-assisted surgical platform, the stock's valuation is seen as elevated. Investors are closely watching future procedure growth and cash flow to determine if the current premium is sustainable.

    AD HOC NEWS•8/30/26•
    Somewhat-Bearish

    Frequently Asked Questions About ISRG

    Does ISRG pay dividends?
    Intuitive Surgical Inc (ISRG) does not currently pay a regular dividend.
    What is ISRG's P/E ratio?
    Intuitive Surgical Inc has a price-to-earnings (P/E) ratio of 36.84.
    What is ISRG's market cap?
    Intuitive Surgical Inc (ISRG) has a market capitalization of $135.02B with a current stock price of $376.86.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In